French Society of Neurovascular – Société Française Neuro-Vasculaire (SFNV)

Lys Therapeutics announces to attend the 27th Days of the French Society of Neurovascular (#SFNV), in #Paris, 16-18 November 2022.

Dr. Manuel BLANC, CEO, and Laurent CONTAUT, CDO, are looking forward to meeting you there!

Program to be find attached or here: https://lnkd.in/eR2bGSVe

💪 All together against Stroke and its dramatic consequences.


With Institut BB@C – Blood and Brain @ Caen normandie and CYCERON.

#SFNV #aviesan #Stroke #neurosciences #clinicaltrials #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #brain #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #biotherapy #Glunomab #Glunozumab

Oral presentation – SFNV 2022

🔬🧠 “Gluno(zu)mab : a disruptive strategy to treat neurological disorders” // “Gluno(zu)mab : une stratégie unique au monde pour traiter les maladies neurovasculaires”

🎤 Dr. Manuel BLANC, CEO of Lys Therapeutics is presenting on November 18, 2022 during the #aviesan session (French National Alliance for Life Sciences and Healthcare) during the 27th Days of the French Society of Neurovascular (#SFNV) in Paris new promising data with Lys Therapeutics’s lead candidate in ischemic stroke.

With Institut BB@C – Blood and Brain @ Caen normandie, Inserm, Inserm Transfert, Université de Caen Normandie and CYCERON.

Link for the full program: https://lnkd.in/eR2bGSVe

#SFNV #aviesan #Stroke #neurosciences #patients #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #brain #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #biotherapy #Glunomab #Glunozumab